Research programme: cocaine antagonists - Zebra PharmaceuticalsAlternative Names: Cocaine antagonists research programme - Zebra Pharmaceuticals
Latest Information Update: 20 Sep 2004
At a glance
- Originator Zebra Pharmaceuticals
- Class Piperidines
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cocaine abuse
Most Recent Events
- 20 Sep 2004 Discontinued - Preclinical for Cocaine abuse in USA (unspecified route)
- 11 Oct 2002 No development reported - Preclinical for Cocaine abuse in USA (unspecified route)
- 19 Jan 2000 New profile